Literature DB >> 15747503

Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5).

Christoph A Ritter1, Gabriele Jedlitschky, Henriette Meyer zu Schwabedissen, Markus Grube, Kathleen Köck, Heyo K Kroemer.   

Abstract

Like other members of the multidrug resistance protein (MRP)/ABCC subfamily of ATP-binding cassette transporters, MRP4 (ABCC4) and MRP5 (ABCC5) are organic anion transporters. They have, however, the outstanding ability to transport nucleotides and nucleotide analogs. In vitro experiments using drug-selected or -transfected cells indicated that these transport proteins, when overexpressed, can lower the intracellular concentration of nucleoside/nucleotide analogs, such as the antiviral compounds PMEA (9-(2-phosphonylmethoxyethyl)adenine) or ganciclovir, and of anticancer nucleobase analogs, such as 6-mercaptopurine, after their conversion into the respective nucleotides. This may lead to an impaired ability of these compounds to inhibit virus replication or cell proliferation. It remains to be tested whether antiviral or anticancer chemotherapy based on nucleobase, nucleoside, or nucleotide precursors can be modulated by inhibition of MRP4 and MRP5. MRP4 also seems to be able to mediate the transport of conjugated steroids, prostaglandins, and glutathione. Furthermore, cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanine monophosphate) are exported from cells by MRP4 and MRP5. This may modulate the intracellular concentration of these important mediators, besides the action of phosphodiesterases, as well as provide extracellular nucleotides for a possible paracrine action. In this line, tissue distribution and subcellular localization of MRP4 and MRP5 specifically in smooth muscle cells (MRP5), platelet-dense granules (MRP4), and nervous cells (MRP4 and MRP5), besides the capillary endothelium, point not only to a possible function of these transporters as exporters in cellular defense, but also to a physiological function in signaling processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15747503     DOI: 10.1081/dmr-200047984

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  52 in total

1.  Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice.

Authors:  Benoit Decouture; Elise Dreano; Tiphaine Belleville-Rolland; Orjeta Kuci; Blandine Dizier; Amine Bazaa; Bérard Coqueran; Anne-Marie Lompre; Cécile V Denis; Jean-Sébastien Hulot; Christilla Bachelot-Loza; Pascale Gaussem
Journal:  Blood       Date:  2015-08-27       Impact factor: 22.113

Review 2.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

Review 3.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

4.  MRP4 and CFTR in the regulation of cAMP and β-adrenergic contraction in cardiac myocytes.

Authors:  Zachary M Sellers; Anjaparavanda P Naren; Yang Xiang; Philip M Best
Journal:  Eur J Pharmacol       Date:  2012-02-20       Impact factor: 4.432

5.  Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Authors:  Laurence Bousquet; Alain Pruvost; Anne-Cécile Guyot; Robert Farinotti; Aloïse Mabondzo
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Dependence of multidrug resistance protein-mediated cyclic nucleotide efflux on the background sodium conductance.

Authors:  Marek Kucka; Karla Kretschmannova; Takayo Murano; Chung-Pu Wu; Hana Zemkova; Suresh V Ambudkar; Stanko S Stojilkovic
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

7.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

Review 8.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

9.  Forskolin modifies retinal vascular development in Mrp4-knockout mice.

Authors:  Wataru Matsumiya; Sentaro Kusuhara; Keiko Hayashibe; Kazuichi Maruyama; Hiroyuki Kusuhara; Mizuki Tagami; John D Schuetz; Akira Negi
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-07       Impact factor: 4.799

10.  Effluxing ABC transporters in human corneal epithelium.

Authors:  Kati-Sisko Vellonen; Eliisa Mannermaa; Helen Turner; Marika Häkli; J Mario Wolosin; Timo Tervo; Paavo Honkakoski; Arto Urtti
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.